302 related articles for article (PubMed ID: 21965052)
1. Expression of Ki-67 as proliferation biomarker in imprint smears of endometrial carcinoma.
Kosmas K; Stamoulas M; Marouga A; Kavantzas N; Patsouris E; Athanassiadou P
Diagn Cytopathol; 2013 Mar; 41(3):212-7. PubMed ID: 21965052
[TBL] [Abstract][Full Text] [Related]
2. Expression of p53 in imprint smears of endometrial carcinoma.
Kosmas K; Stamoulas M; Marouga A; Kavantzas N; Patsouris E; Athanassiadou P
Diagn Cytopathol; 2014 May; 42(5):416-22. PubMed ID: 24167025
[TBL] [Abstract][Full Text] [Related]
3. The use of an immunocytochemical double-labeling staining can display the distribution of Bcl-2/Ki-67 cells in endometrial adenocarcinomas as well as in normal endometrium.
Mourtzikou A; Kosmas K; Marouga A; Stamouli M; Pouliakis A; Karakitsos P
Clin Lab; 2012; 58(1-2):133-44. PubMed ID: 22372356
[TBL] [Abstract][Full Text] [Related]
4. Expression of phosphatase and tensin homologue in imprint smears of endometrial carcinoma.
Kosmas K; Mitropoulou G; Provatas I; Stamoulas M; Marouga A
Cytopathology; 2018 Dec; 29(6):558-564. PubMed ID: 30007089
[TBL] [Abstract][Full Text] [Related]
5. Expression of cyclooxygenase-2 in imprint smears of endometrial carcinoma.
Kosmas K; Mitropoulou G; Stamoulas M; Marouga A
Diagn Cytopathol; 2020 Nov; 48(11):1086-1092. PubMed ID: 32433831
[TBL] [Abstract][Full Text] [Related]
6. Cytodiagnosis of endometrial carcinoma and hyperplasia on imprint smears with additional immunocytochemistry using Ki-67 and p53 biomarkers.
Apostolou G; Apostolou N; Nikolaidou C; Kavantzas N; Patsouris E; Athanassiadou P
Cytopathology; 2014 Apr; 25(2):86-94. PubMed ID: 24118263
[TBL] [Abstract][Full Text] [Related]
7. Utility of Ki-67, p53, Bcl-2, and Cox-2 biomarkers for low-grade endometrial cancer and disordered proliferative/benign hyperplastic endometrium by imprint cytology.
Apostolou G; Apostolou N; Biteli M; Kavantzas N; Patsouris E; Athanassiadou P
Diagn Cytopathol; 2014 Feb; 42(2):134-42. PubMed ID: 23729350
[TBL] [Abstract][Full Text] [Related]
8. Cyclin D1 and Ki-67 expression in normal, hyperplastic and neoplastic endometrium.
Shevra CR; Ghosh A; Kumar M
J Postgrad Med; 2015; 61(1):15-20. PubMed ID: 25511212
[TBL] [Abstract][Full Text] [Related]
9. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
[TBL] [Abstract][Full Text] [Related]
10. L-type amino acid transporter 1 expression increases in well-differentiated but decreases in poorly differentiated endometrial endometrioid adenocarcinoma and shows an inverse correlation with p53 expression.
Watanabe J; Yokoyama Y; Futagami M; Mizunuma H; Yoshioka H; Washiya K; Hana K; Endou H; Okayasu I
Int J Gynecol Cancer; 2014 May; 24(4):659-63. PubMed ID: 24694899
[TBL] [Abstract][Full Text] [Related]
11. Expression of cyclin D1 in normal, hyperplastic and neoplastic endometrium and its correlation with Ki-67 and clinicopathological variables.
Ozuysal S; Oztürk H; Bilgin T; Filiz G
Arch Gynecol Obstet; 2005 Feb; 271(2):123-6. PubMed ID: 14740230
[TBL] [Abstract][Full Text] [Related]
12. p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry.
Fadare O; Parkash V
Diagn Pathol; 2017 Nov; 12(1):81. PubMed ID: 29137657
[TBL] [Abstract][Full Text] [Related]
13. Proliferative activity in postmenopausal endometrium: the lurking potential for giving rise to an endometrial adenocarcinoma.
Sivridis E; Giatromanolaki A
J Clin Pathol; 2004 Aug; 57(8):840-4. PubMed ID: 15280405
[TBL] [Abstract][Full Text] [Related]
14. GLUT-1 Expression in Proliferative Endometrium, Endometrial Hyperplasia, Endometrial Adenocarcinoma and the Relationship Between GLUT-1 Expression and Prognostic Parameters in Endometrial Adenocarcinoma.
Canpolat T; Ersöz C; Uğuz A; Vardar MA; Altintaş A
Turk Patoloji Derg; 2016; 32(3):141-7. PubMed ID: 27562387
[TBL] [Abstract][Full Text] [Related]
15. Endometrial cytopathology. An image analysis approach using the Ki-67 biomarker.
Apostolou G; Apostolou N; Moulos P; Chatzipantelis P
Cytopathology; 2017 Oct; 28(5):385-390. PubMed ID: 28737230
[TBL] [Abstract][Full Text] [Related]
16. Lymphovascular space invasion does not predict vaginal relapses in stage I endometrioid adenocarcinoma of the endometrium.
Desrosiers L; Fadare O; Xiao ZF; Dresser K; Wang SA
Ann Diagn Pathol; 2008 Apr; 12(2):112-7. PubMed ID: 18325471
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of DNA topoisomerase II-alpha (Ki-S1) immunoexpression in endometrial carcinoma.
Bildrici K; Tel N; Ozalp SS; Yalcin OT; Yilmaz V
Eur J Gynaecol Oncol; 2002; 23(6):540-4. PubMed ID: 12556100
[TBL] [Abstract][Full Text] [Related]
18. Effects of forkhead box C2 on carcinogenesis and lymphatic metastasis in endometrial carcinoma.
Fan YY; Deng WG; Liu YN; Li YY; Deng SL; Fu Y
Genet Mol Res; 2015 May; 14(2):5535-47. PubMed ID: 26125751
[TBL] [Abstract][Full Text] [Related]
19. Cyclin D1 expression in endometrioid-type endometrial adenocarcinoma is correlated with histological grade and proliferative activity, but not with prognosis.
Nishimura Y; Watanabe J; Jobo T; Kato N; Fujisawa T; Kamata Y; Kuramoto H
Anticancer Res; 2004; 24(4):2185-91. PubMed ID: 15330159
[TBL] [Abstract][Full Text] [Related]
20. Cytokeratin 19 expression in normal endometrium and in low-grade endometrioid adenocarcinoma of the endometrium.
Stewart CJ; Crook ML; Lacey J; Louwen K
Int J Gynecol Pathol; 2011 Sep; 30(5):484-91. PubMed ID: 21804393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
